Cargando…

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation

AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Keith A A, Virdone, Saverio, Pieper, Karen S, Bassand, Jean-Pierre, Camm, A John, Fitzmaurice, David A, Goldhaber, Samuel Z, Goto, Shinya, Haas, Sylvia, Kayani, Gloria, Oto, Ali, Misselwitz, Frank, Piccini, Jonathan P, Dalgaard, Frederik, Turpie, Alexander G G, Verheugt, Freek W A, Kakkar, Ajay K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888127/
https://www.ncbi.nlm.nih.gov/pubmed/33892489
http://dx.doi.org/10.1093/ehjqcco/qcab028
_version_ 1784661065806643200
author Fox, Keith A A
Virdone, Saverio
Pieper, Karen S
Bassand, Jean-Pierre
Camm, A John
Fitzmaurice, David A
Goldhaber, Samuel Z
Goto, Shinya
Haas, Sylvia
Kayani, Gloria
Oto, Ali
Misselwitz, Frank
Piccini, Jonathan P
Dalgaard, Frederik
Turpie, Alexander G G
Verheugt, Freek W A
Kakkar, Ajay K
author_facet Fox, Keith A A
Virdone, Saverio
Pieper, Karen S
Bassand, Jean-Pierre
Camm, A John
Fitzmaurice, David A
Goldhaber, Samuel Z
Goto, Shinya
Haas, Sylvia
Kayani, Gloria
Oto, Ali
Misselwitz, Frank
Piccini, Jonathan P
Dalgaard, Frederik
Turpie, Alexander G G
Verheugt, Freek W A
Kakkar, Ajay K
author_sort Fox, Keith A A
collection PubMed
description AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared with CHA(2)DS(2)-VASc and HAS-BLED. METHODS AND RESULTS: Potential predictors of events included demographic and clinical characteristics, choice of treatment, and lifestyle factors. A Cox proportional hazards model was identified for each outcome by least absolute shrinkage and selection operator methods. Indices were evaluated in comparison with CHA(2)DS(2)-VASc and HAS-BLED risk predictors. Models were validated internally and externally in ORBIT-AF and Danish nationwide registries. Among the 52 080 patients enrolled in GARFIELD-AF, 52 032 had follow-up data. The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc for all-cause mortality in all cohorts. The GARFIELD-AF risk score was superior to CHA(2)DS(2)-VASc for non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in internal validation and in the Danish AF cohort. In very low- to low-risk patients [CHA(2)DS(2)-VASc 0 or 1 (men) and 1 or 2 (women)], the GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when compared to CHA(2)DS(2)-VASc and HAS-BLED. The GARFIELD-AF tool also included the effect of oral anticoagulation (OAC) therapy, thus allowing clinicians to compare the expected outcome of different anticoagulant treatment decisions [i.e. no OAC, non-vitamin K antagonist (VKA) oral anticoagulants, or VKAs]. CONCLUSIONS: The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc at predicting death and non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as in very low- to low-risk group patients with AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362, ORBIT-AF I: NCT01165710; ORBIT-AF II: NCT01701817.
format Online
Article
Text
id pubmed-8888127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-88881272022-03-02 GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation Fox, Keith A A Virdone, Saverio Pieper, Karen S Bassand, Jean-Pierre Camm, A John Fitzmaurice, David A Goldhaber, Samuel Z Goto, Shinya Haas, Sylvia Kayani, Gloria Oto, Ali Misselwitz, Frank Piccini, Jonathan P Dalgaard, Frederik Turpie, Alexander G G Verheugt, Freek W A Kakkar, Ajay K Eur Heart J Qual Care Clin Outcomes Original Article AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared with CHA(2)DS(2)-VASc and HAS-BLED. METHODS AND RESULTS: Potential predictors of events included demographic and clinical characteristics, choice of treatment, and lifestyle factors. A Cox proportional hazards model was identified for each outcome by least absolute shrinkage and selection operator methods. Indices were evaluated in comparison with CHA(2)DS(2)-VASc and HAS-BLED risk predictors. Models were validated internally and externally in ORBIT-AF and Danish nationwide registries. Among the 52 080 patients enrolled in GARFIELD-AF, 52 032 had follow-up data. The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc for all-cause mortality in all cohorts. The GARFIELD-AF risk score was superior to CHA(2)DS(2)-VASc for non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in internal validation and in the Danish AF cohort. In very low- to low-risk patients [CHA(2)DS(2)-VASc 0 or 1 (men) and 1 or 2 (women)], the GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when compared to CHA(2)DS(2)-VASc and HAS-BLED. The GARFIELD-AF tool also included the effect of oral anticoagulation (OAC) therapy, thus allowing clinicians to compare the expected outcome of different anticoagulant treatment decisions [i.e. no OAC, non-vitamin K antagonist (VKA) oral anticoagulants, or VKAs]. CONCLUSIONS: The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc at predicting death and non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as in very low- to low-risk group patients with AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362, ORBIT-AF I: NCT01165710; ORBIT-AF II: NCT01701817. Oxford University Press 2021-05-25 /pmc/articles/PMC8888127/ /pubmed/33892489 http://dx.doi.org/10.1093/ehjqcco/qcab028 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Fox, Keith A A
Virdone, Saverio
Pieper, Karen S
Bassand, Jean-Pierre
Camm, A John
Fitzmaurice, David A
Goldhaber, Samuel Z
Goto, Shinya
Haas, Sylvia
Kayani, Gloria
Oto, Ali
Misselwitz, Frank
Piccini, Jonathan P
Dalgaard, Frederik
Turpie, Alexander G G
Verheugt, Freek W A
Kakkar, Ajay K
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title_full GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title_fullStr GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title_full_unstemmed GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title_short GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
title_sort garfield-af risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888127/
https://www.ncbi.nlm.nih.gov/pubmed/33892489
http://dx.doi.org/10.1093/ehjqcco/qcab028
work_keys_str_mv AT foxkeithaa garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT virdonesaverio garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT pieperkarens garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT bassandjeanpierre garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT cammajohn garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT fitzmauricedavida garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT goldhabersamuelz garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT gotoshinya garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT haassylvia garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT kayanigloria garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT otoali garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT misselwitzfrank garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT piccinijonathanp garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT dalgaardfrederik garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT turpiealexandergg garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT verheugtfreekwa garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT kakkarajayk garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation
AT garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation